<DOC>
	<DOCNO>NCT00239967</DOCNO>
	<brief_summary>The purpose study assess effect rimonabant 20 mg HDL ( high density lipoprotein ) cholesterol TG ( triglyceride ) plasma level period one year prescribe hypocaloric diet ( 600 kcal deficit per day ) abdominally obese patient atherogenic dyslipidemia ( low HDL and/or high TG plasma level ) . The secondary objective evaluate specific metabolic parameter , visceral fat ( select site ) , safety tolerability rimonabant 20 mg .</brief_summary>
	<brief_title>An International Study Rimonabant Dyslipidemia With AtheroGenic Risk In Abdominally Obese Patients</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Rimonabant</mesh_term>
	<criteria>Male female patient age &gt; = 18 year Waist circumference &gt; 102 cm men &gt; 88 cm woman Dyslipidemia consist : Triglyceridemia &gt; = 1.5g/L ( i.e . 1.69mmol/L ) ≤ 7.0g/L ( i.e . 7.90mmol/L ) AND/OR HDL cholesterol &lt; 50mg/dL ( 1.29mmol/L ) woman , &lt; 40mg/dL ( 1.04mmol/L ) men If patient type 2 diabetes include must stable dose oral antidiabetic medication ( exclude glitazones ) insulin therapy Written inform consent Weight change &gt; 5 kg within 3 month prior screen visit Pregnancy lactation , woman plan become pregnant Absence medically approve contraceptive method female childbearing potential Presence condition ( e.g . geographic , social… ) actual anticipate , Investigator feel would restrict limit subject 's participation duration study . Presence clinically significant endocrine disease ( type 2 diabetes ) accord Investigator History severe depression could define depression necessitated patient hospitalize , patient 2 recurrent episode depression history suicide attempt . Presence history DSMIV bulimia anorexia nervosa Positive test hepatitis B surface antigen and/or hepatitis C antibody ; Abnormal TSH level ( TSH &gt; ULN &lt; LLN ) ; Hemoglobin &lt; 11g/dL and/or neutrophil &gt; 1,500/mm3 and/or platelet &lt; 100,000/mm3 ; Positive urine pregnancy test female childbearing potential . Within 3 month prior screen visit screen inclusion visit : Administration anti obesity drug ( e.g. , sibutramine , orlistat ) Administration drug weight reduction include herbal preparation ( phentermine , amphetamine ) Thyroid preparation thyroxine treatment ( except patient replacement therapy stable dose ) If patient type 2 diabetes include must stable dose oral antidiabetic medication least 3 month expect receive insulin therapy within 12 month : Insulin , Glitazones Any change lipid lowering treatment ( i.e . introduction new drug , change , cessation ) Administration systemic longacting corticosteroid Prolonged use ( 1 week ) systemic corticosteroid ( daily dosage &gt; 1000 µg equivalent beclomethasone Prolonged administration ( one week ) antidepressant ( include bupropion ) Prolonged administration ( one week ) neuroleptic .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>dyslipidemia</keyword>
	<keyword>obesity</keyword>
</DOC>